Physician, Division of General Internal Medicine, Massachusetts General Hospital and Co-Director of the MGH Clinical Research Program’s Clinical Effectiveness Research Group
Professor of Medicine at Harvard Medical School

Dr. Meigs major research interest is the cause and prevention of type 2 diabetes and cardiovascular disease. He has used biochemical and genetic epidemiology and health services translational research approaches. As of May 2019, in Web of Science, Dr. Meigs has 663 scientific publications with an h-index of 113 with over 57,000 cited articles, and during 2014-2016, he was one of Thompson-Reuters “Highly Cited Investigators”. In 2009, he was awarded the ADA’s prestigious Kelly West Award for Outstanding Achievement in Diabetes Epidemiology.


Dr. Meigs is a senior leader of many major large international T2D genomics consortia, including MAGIC, DIAGRAM, AAGILE, CHARGE- and TOPMed-diabetes and NIDDK T2D AMP. He is the PI, co-PI or co-investigator on many NIH grants, currently including 5U01 DK078616-10: Rare Genetic Variation and Diabetes Quantitative Traits. Dr. Meigs is a member of the steering committee of the NIDDK Accelerating Medicines Partnership (AMP) - Type 2 Diabetes and of the NIDDK's Diabetes in America, volume 3. He has formally mentored over 50 early career investigators (including nine K23/K01/K99 mentees), most of whom have remained in academic medicine, and he is an MGH Institutional Research Mentor. In addition, for 30 years he has been a practicing primary care general internist at MGH.